Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ADAM19 (ImmuneEditome ID:8728)

1. Gene summary of enriched editing regions for ADAM19

Gene summary

Gene information	Gene symbol	ADAM19
	Gene ID	8728
	GeneSynonyms	FKSG34\|MADDAM\|MLTNB
	GeneCytomap	5q33.3
	GeneType	protein-coding
	GeneDescription	disintegrin and metalloproteinase domain-containing protein 19\|a disintegrin and metalloproteinase domain 19 (meltrin beta)\|metalloprotease and disintegrin dendritic antigen marker\|metalloprotease-disintegrin meltrin beta
	GeneModificationdate	20230517
	UniprotID	Q9H013;Q8TBU7;E5RIS2
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr5:157477872-157478606:-	ENST00000257527.7	ENSG00000135074.14	ADAM19	UTR3	MER92B,MER67C	chr5:157477872-157478606:-.alignment
chr5:157501783-157501986:-	ENST00000257527.7	ENSG00000135074.14	ADAM19	intronic	AluSx	chr5:157501783-157501986:-.alignment
chr5:157501783-157501986:-	ENST00000517374.4	ENSG00000135074.14	ADAM19	intronic	AluSx	chr5:157501783-157501986:-.alignment
chr5:157501783-157501986:-	ENST00000517905.1	ENSG00000135074.14	ADAM19	intronic	AluSx	chr5:157501783-157501986:-.alignment
chr5:157501783-157501986:-	ENST00000517951.4	ENSG00000135074.14	ADAM19	intronic	AluSx	chr5:157501783-157501986:-.alignment

Top

2. Tumor-specific enriched editing regions for ADAM19

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr5:157477872-157478606:-	BRCA	EER	3.0947e-02
ENSG00000135074.14,ADAM19	BRCA	EAG	4.4015e-03
chr5:157477872-157478606:-	COAD	EER	2.1390e-04
ENSG00000135074.14,ADAM19	COAD	EAG	1.1033e-03
chr5:157477872-157478606:-	KIRC	EER	3.2525e-03
ENSG00000135074.14,ADAM19	KIRC	EAG	4.5757e-03
chr5:157477872-157478606:-	LUSC	EER	2.7176e-03
ENSG00000135074.14,ADAM19	LUSC	EAG	1.4414e-02
chr5:157477872-157478606:-	PRAD	EER	1.2717e-02
ENSG00000135074.14,ADAM19	PRAD	EAG	1.8351e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr5:157477872-157478606:-	CHOL	Path	EER	3.6680e-02	9.1323e-03	0.4755
chr5:157477872-157478606:-	DLBC	Cli	EER	4.4477e-02	9.6737e-03	-0.3948
chr5:157477872-157478606:-	ESCA	Path	EER	4.0634e-02	4.1267e-02	0.1734
chr5:157477872-157478606:-	HNSC	Cli	EER	1.8858e-03	3.2243e-03	0.1395
ENSG00000135074.14,ADAM19	KIRC	Path	EAG	4.8718e-02	2.6094e-02	0.1009
chr5:157477872-157478606:-	LUAD	Path	EER	2.8958e-03	2.5595e-03	0.1391
ENSG00000135074.14,ADAM19	LUAD	Path	EAG	1.8668e-02	1.9309e-02	0.1069
ENSG00000135074.14,ADAM19	LUSC	Path	EAG	5.6830e-03	1.6239e-03	0.1438
chr5:157477872-157478606:-	LUSC	Path	EER	4.5300e-03	1.0189e-03	0.1530

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
ENSG00000135074.14,ADAM19	LGG	EAG	4.9035e-02	3.2115e-02	9.7486e-02

Top

3. Enriched editing regions and immune related genes for ADAM19

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr5:157477872-157478606:-

GBM

EER

ENSG00000145832,SLC25A48

0.3332

7.2389e-03

8.8616e-07

0.4069

Plasma_cells

GSVA_HALLMARK_ANGIOGENESIS

chr5:157477872-157478606:-

STAD

EER

ENSG00000237506,RPSAP15

0.2202

1.1785e-03

1.4618e-16

0.4195

Dendritic_cells_activated

GSVA_HALLMARK_UV_RESPONSE_DN

chr5:157477872-157478606:-

STAD

EER

ENSG00000240087,RP11-254B13.1

0.1654

2.2176e-02

3.6776e-16

0.4144

Dendritic_cells_activated

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr5:157477872-157478606:-

KIRC

EER

ENSG00000279117,CTD-2562J17.6

-0.3976

2.4381e-10

1.3177e-15

-0.4198

T_cells_follicular_helper

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr5:157477872-157478606:-

DLBC

EER

ENSG00000281404,LINC01176

-0.6124

1.4117e-02

1.1377e-05

-0.5927

Mast_cells_activated

GSVA_HALLMARK_SPERMATOGENESIS

chr5:157477872-157478606:-

DLBC

EER

ENSG00000265206,RP5-1171I10.5

-0.5937

2.2138e-02

1.4821e-03

-0.4506

GSVA_HALLMARK_HYPOXIA

chr5:157477872-157478606:-

DLBC

EER

ENSG00000207757,MIR93

-0.5409

3.3791e-02

3.1874e-05

-0.5675

B_cells_naive

GSVA_HALLMARK_APICAL_SURFACE

chr5:157477872-157478606:-

DLBC

EER

ENSG00000199133,MIRLET7D

-0.5742

3.4408e-02

1.9293e-03

-0.4408

B_cells_naive

GSVA_HALLMARK_COAGULATION

chr5:157477872-157478606:-

DLBC

EER

ENSG00000153790,C7orf31

-0.5406

4.1137e-02

6.9741e-04

-0.4771

Macrophages_M2

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr5:157477872-157478606:-

DLBC

EER

ENSG00000095370,SH2D3C

-0.5602

4.4721e-02

7.8154e-04

-0.4732

B_cells_naive

GSVA_HALLMARK_PANCREAS_BETA_CELLS

More results

Top

4. Enriched editing regions and immune related splicing for ADAM19

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr5:157477872-157478606:-

COAD

EER

MEX

ENSG00000214078.7

chr20

35627284:35627413:35630438:35630455:35630740:35630795:35630900:35631034

0.2444

1.7156e-02

1.4002e-15

0.4660

Dendritic_cells_activated

GSVA_HALLMARK_SPERMATOGENESIS

ENSG00000135074.14,ADAM19

GBM

EAG

ENSG00000150787.3

chr11

112228593:112228673:112230207:112230230:112230625:112230682

-0.4218

1.2269e-03

2.7741e-08

-0.4412

ADAR;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28;LIN28B;MOV10;MSI1;NOP56;NOP58;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF10;SRSF3;TAF15;TARBP2;TARDBP;U2AF1;U2AF2;UPF1;XRN2;YTHDC1

Monocytes

GSVA_HALLMARK_MYC_TARGETS_V2

ENSG00000135074.14,ADAM19

GBM

EAG

ENSG00000150787.3

chr11

112228593:112228673:112230625:112230682:112230207:112230682

0.4196

1.3555e-03

2.3158e-08

0.4435

Monocytes

GSVA_HALLMARK_MYC_TARGETS_V2

ENSG00000135074.14,ADAM19

GBM

EAG

ENSG00000133816.9

chr11

12262479:12262635:12263559:12263588

-0.2670

2.7846e-02

1.8961e-06

-0.4112

ADAR;CNBP;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM47;SRSF1;SRSF10;SRSF3;TAF15;TARDBP;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1

NK_cells_activated

GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

chr5:157477872-157478606:-

EER

ENSG00000121350.11

chr12

21449562:21449691:21452080:21452154:21455131:21455292

-0.2010

2.4502e-02

3.5570e-09

-0.4381

ENSG00000135074.14,ADAM19

PAAD

EAG

ENSG00000133392.12

chr16

15724160:15724992:15726847:15727054

0.3894

3.5632e-03

1.3230e-08

0.4210

ADAR;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;LIN28B;MBNL2;NOP56;NOP58;PTBP1;PUM2;RBFOX2;SRSF1;SRSF10;SRSF3;TAF15;TROVE2;U2AF2;UPF1

NK_cells_activated

GSVA_HALLMARK_MYOGENESIS

chr5:157477872-157478606:-

PAAD

EER

ENSG00000133392.12

chr16

15724160:15724409:15724646:15724691

0.3984

3.4352e-03

2.6132e-08

0.4178

B_cells_naive

GSVA_HALLMARK_MYOGENESIS

ENSG00000135074.14,ADAM19

PAAD

EAG

ENSG00000133392.12

chr16

15724160:15724409:15724646:15724691

0.4070

1.7432e-03

1.9798e-09

0.4421

ADAR;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;LIN28B;MBNL2;NOP56;NOP58;PTBP1;PUM2;RBFOX2;SRSF1;SRSF10;SRSF3;TAF15;TROVE2;U2AF2;UPF1

B_cells_naive

GSVA_HALLMARK_MYOGENESIS

ENSG00000135074.14,ADAM19

PAAD

EAG

ENSG00000133392.12

chr16

15724160:15724799:15724887:15724992

0.3798

5.9858e-03

1.7993e-08

0.4175

ADAR;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;LIN28B;MBNL2;NOP56;NOP58;PTBP1;PUM2;RBFOX2;SRSF1;SRSF10;SRSF3;TAF15;TROVE2;U2AF2;UPF1

NK_cells_activated

GSVA_HALLMARK_MYOGENESIS

chr5:157477872-157478606:-

SARC

EER

ENSG00000130175.5

chr19

11449265:11449882:11450428:11450716

-0.3926

1.4725e-05

6.0450e-11

-0.4045

PRKCSH

T_cells_CD8

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

More results

Top

5. Enriched editing regions and immune infiltration for ADAM19

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr5:157477872-157478606:-	BLCA	EER	Macrophages_M1	4.8860e-03	0.1624
ENSG00000135074.14,ADAM19	BLCA	EAG	B_cells_memory	1.3311e-03	-0.1784
chr5:157477872-157478606:-	BRCA	EER	Macrophages_M0	2.1814e-04	-0.1180
ENSG00000135074.14,ADAM19	BRCA	EAG	Macrophages_M0	3.1295e-07	-0.1596
chr5:157477872-157478606:-	CESC	EER	Dendritic_cells_activated	2.4650e-03	0.1863
ENSG00000135074.14,ADAM19	CESC	EAG	Dendritic_cells_activated	1.0057e-03	0.1955
chr5:157477872-157478606:-	COAD	EER	Macrophages_M2	1.3875e-02	-0.1516
ENSG00000135074.14,ADAM19	COAD	EAG	Plasma_cells	1.5106e-02	-0.1483
chr5:157477872-157478606:-	ESCA	EER	NK_cells_activated	6.0870e-03	0.2194
ENSG00000135074.14,ADAM19	ESCA	EAG	NK_cells_activated	3.9470e-03	0.2288
chr5:157477872-157478606:-	GBM	EER	Monocytes	4.3740e-04	0.2974
ENSG00000135074.14,ADAM19	GBM	EAG	NK_cells_activated	8.3574e-04	0.2745
chr5:157477872-157478606:-	HNSC	EER	T_cells_regulatory_(Tregs)	2.1438e-03	-0.1432
ENSG00000135074.14,ADAM19	HNSC	EAG	Dendritic_cells_activated	1.1037e-04	0.1752
chr5:157477872-157478606:-	KIRC	EER	T_cells_CD4_naive	1.8064e-02	-0.1297
ENSG00000135074.14,ADAM19	KIRC	EAG	Eosinophils	1.4992e-02	0.1301
chr5:157477872-157478606:-	KIRP	EER	Eosinophils	4.8157e-02	0.2781
ENSG00000135074.14,ADAM19	KIRP	EAG	NK_cells_resting	1.3678e-02	-0.2894
ENSG00000135074.14,ADAM19	LAML	EAG	Macrophages_M1	2.2568e-03	0.4305
chr5:157477872-157478606:-	LGG	EER	Monocytes	7.2064e-03	0.1583
ENSG00000135074.14,ADAM19	LGG	EAG	Monocytes	2.6534e-05	0.2177
chr5:157477872-157478606:-	LIHC	EER	Mast_cells_resting	2.0795e-02	0.1462
ENSG00000135074.14,ADAM19	LIHC	EAG	Mast_cells_resting	5.6680e-04	0.1988
chr5:157477872-157478606:-	LUAD	EER	T_cells_CD4_memory_resting	5.2800e-03	-0.1290
ENSG00000135074.14,ADAM19	LUAD	EAG	B_cells_naive	2.3393e-02	0.1038
chr5:157477872-157478606:-	LUSC	EER	T_cells_CD4_memory_resting	3.0752e-04	-0.1677
ENSG00000135074.14,ADAM19	LUSC	EAG	T_cells_CD4_memory_resting	2.5498e-04	-0.1664
ENSG00000135074.14,ADAM19	MESO	EAG	T_cells_follicular_helper	2.1039e-02	0.2661
chr5:157477872-157478606:-	OV	EER	T_cells_follicular_helper	6.9850e-03	0.1856
ENSG00000135074.14,ADAM19	OV	EAG	T_cells_follicular_helper	1.9103e-06	0.3018
chr5:157477872-157478606:-	PAAD	EER	B_cells_naive	3.8449e-03	-0.2246
ENSG00000135074.14,ADAM19	PAAD	EAG	B_cells_naive	9.3287e-03	-0.1995
ENSG00000135074.14,ADAM19	PCPG	EAG	Neutrophils	1.8198e-02	0.2739
chr5:157477872-157478606:-	PRAD	EER	Eosinophils	5.5029e-03	0.1951
ENSG00000135074.14,ADAM19	PRAD	EAG	T_cells_CD4_memory_activated	3.6560e-02	-0.1261
chr5:157477872-157478606:-	READ	EER	Dendritic_cells_resting	2.6736e-03	0.3096
ENSG00000135074.14,ADAM19	READ	EAG	Dendritic_cells_resting	1.0384e-02	0.2660
chr5:157477872-157478606:-	SARC	EER	T_cells_gamma_delta	3.6064e-03	0.1864
ENSG00000135074.14,ADAM19	SARC	EAG	Macrophages_M0	6.1241e-03	-0.1733
chr5:157477872-157478606:-	SKCM	EER	T_cells_CD8	4.0498e-04	0.1834
ENSG00000135074.14,ADAM19	SKCM	EAG	T_cells_CD8	2.9126e-04	0.1804
chr5:157477872-157478606:-	STAD	EER	T_cells_follicular_helper	2.7456e-04	0.1920
ENSG00000135074.14,ADAM19	STAD	EAG	T_cells_CD8	1.8114e-05	0.2223
chr5:157477872-157478606:-	TGCT	EER	Macrophages_M2	2.5757e-06	-0.3719
ENSG00000135074.14,ADAM19	TGCT	EAG	Macrophages_M2	2.5905e-08	-0.4301
ENSG00000135074.14,ADAM19	THCA	EAG	NK_cells_resting	1.8822e-03	0.1762
chr5:157477872-157478606:-	THYM	EER	Monocytes	3.6916e-02	0.2144
ENSG00000135074.14,ADAM19	THYM	EAG	Mast_cells_activated	6.8045e-03	0.2578
ENSG00000135074.14,ADAM19	UCEC	EAG	Dendritic_cells_activated	1.0532e-03	0.2599

Top

6. Enriched editing regions and immune gene sets for ADAM19

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr5:157477872-157478606:-	BLCA	EER	6.6917e-04		2.5014e-02	-0.1296
chr5:157477872-157478606:-	BRCA	EER	2.7210e-05		7.9316e-03	-0.0849
ENSG00000135074.14,ADAM19	BRCA	EAG	2.1197e-06		1.0545e-02	-0.0802
chr5:157477872-157478606:-	LUSC	EER	9.7493e-04		9.5391e-09	-0.2638
ENSG00000135074.14,ADAM19	LUSC	EAG	1.8132e-02		2.8706e-08	-0.2502

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000135074.14,ADAM19	LGG	EAG	2.2483e-04	-0.1917	1.4364e-10	-0.3270	1.0682e-04	-0.2011	8.0128e-03	-0.1384
chr5:157477872-157478606:-	LGG	EER	1.3411e-03	-0.1884	2.3830e-05	-0.2466	6.3699e-03	-0.1607	4.1104e-02	-0.1207
ENSG00000135074.14,ADAM19	LUAD	EAG	2.0329e-03	0.1409	9.4234e-03	0.1188	1.2181e-02	0.1147	4.0879e-02	0.0937
chr5:157477872-157478606:-	LUAD	EER	1.5560e-02	0.1120	4.9928e-02	0.0909	2.6306e-02	0.1029	4.2784e-02	0.0939

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000135074.14,ADAM19	ACC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	2.8767e-03	0.4487
chr5:157477872-157478606:-	ACC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.0901e-02	0.4581
ENSG00000135074.14,ADAM19	BLCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.0689e-03	0.1818
chr5:157477872-157478606:-	BLCA	GSVA_HALLMARK_MYOGENESIS	EER	3.4318e-03	-0.1687
ENSG00000135074.14,ADAM19	BRCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	4.9690e-07	0.1569
chr5:157477872-157478606:-	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.0497e-06	0.1512
chr5:157477872-157478606:-	CESC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	5.8618e-05	-0.2456
ENSG00000135074.14,ADAM19	CESC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	9.2382e-04	-0.1969
chr5:157477872-157478606:-	CHOL	GSVA_HALLMARK_P53_PATHWAY	EER	3.3553e-03	-0.5264
ENSG00000135074.14,ADAM19	CHOL	GSVA_HALLMARK_P53_PATHWAY	EAG	6.7924e-03	-0.4689
chr5:157477872-157478606:-	COAD	GSVA_HALLMARK_ANGIOGENESIS	EER	4.7692e-04	-0.2139
ENSG00000135074.14,ADAM19	COAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	7.8469e-04	-0.2039
chr5:157477872-157478606:-	DLBC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.3743e-03	0.4329
ENSG00000135074.14,ADAM19	DLBC	GSVA_HALLMARK_HYPOXIA	EAG	6.8400e-03	0.3853
ENSG00000135074.14,ADAM19	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	2.0843e-03	-0.2439
chr5:157477872-157478606:-	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	3.9420e-02	-0.1656
ENSG00000135074.14,ADAM19	GBM	GSVA_HALLMARK_ANGIOGENESIS	EAG	1.1227e-06	-0.3915
chr5:157477872-157478606:-	GBM	GSVA_HALLMARK_ANGIOGENESIS	EER	6.1126e-05	-0.3367
ENSG00000135074.14,ADAM19	HNSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	2.2852e-05	-0.1916
chr5:157477872-157478606:-	HNSC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	2.5270e-04	0.1704
chr5:157477872-157478606:-	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.7691e-08	0.3030
ENSG00000135074.14,ADAM19	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.6986e-08	0.2962
ENSG00000135074.14,ADAM19	KIRP	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.0573e-02	0.2996
chr5:157477872-157478606:-	KIRP	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.7276e-02	-0.3321
chr5:157477872-157478606:-	LAML	GSVA_HALLMARK_MTORC1_SIGNALING	EER	4.8539e-02	0.3180
ENSG00000135074.14,ADAM19	LAML	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.6375e-02	0.3029
ENSG00000135074.14,ADAM19	LGG	GSVA_HALLMARK_ANGIOGENESIS	EAG	5.2333e-11	-0.3343
chr5:157477872-157478606:-	LGG	GSVA_HALLMARK_ANGIOGENESIS	EER	6.3880e-06	-0.2629
ENSG00000135074.14,ADAM19	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	3.4700e-05	0.2378
chr5:157477872-157478606:-	LIHC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	6.0171e-04	-0.2155
chr5:157477872-157478606:-	LUAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.5516e-07	0.2360
ENSG00000135074.14,ADAM19	LUAD	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	8.9303e-08	0.2418
chr5:157477872-157478606:-	LUSC	GSVA_HALLMARK_MYOGENESIS	EER	1.7490e-12	-0.3213
ENSG00000135074.14,ADAM19	LUSC	GSVA_HALLMARK_MYOGENESIS	EAG	3.7993e-11	-0.2961
ENSG00000135074.14,ADAM19	MESO	GSVA_HALLMARK_APICAL_JUNCTION	EAG	1.7126e-03	-0.3561
chr5:157477872-157478606:-	MESO	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	4.3972e-04	-0.4090
chr5:157477872-157478606:-	OV	GSVA_HALLMARK_MYOGENESIS	EER	8.9978e-03	-0.1799
ENSG00000135074.14,ADAM19	OV	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EAG	3.3433e-06	-0.2949
ENSG00000135074.14,ADAM19	PAAD	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	2.5080e-04	0.2781
chr5:157477872-157478606:-	PAAD	GSVA_HALLMARK_MYOGENESIS	EER	2.8501e-03	-0.2316
ENSG00000135074.14,ADAM19	PCPG	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.8578e-02	-0.2731
chr5:157477872-157478606:-	PCPG	GSVA_HALLMARK_APICAL_JUNCTION	EER	1.2289e-02	-0.3355
ENSG00000135074.14,ADAM19	PRAD	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	6.9115e-04	0.2034
chr5:157477872-157478606:-	PRAD	GSVA_HALLMARK_MYC_TARGETS_V1	EER	1.8960e-03	0.2178
ENSG00000135074.14,ADAM19	READ	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	1.3384e-02	-0.2570
chr5:157477872-157478606:-	READ	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	9.2334e-03	-0.2700
chr5:157477872-157478606:-	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	8.7894e-05	0.2494
ENSG00000135074.14,ADAM19	SARC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	9.3572e-05	-0.2450
ENSG00000135074.14,ADAM19	SKCM	GSVA_HALLMARK_ANGIOGENESIS	EAG	9.7202e-05	-0.1939
chr5:157477872-157478606:-	SKCM	GSVA_HALLMARK_PEROXISOME	EER	9.6004e-05	0.2019
ENSG00000135074.14,ADAM19	STAD	GSVA_HALLMARK_E2F_TARGETS	EAG	6.3283e-08	0.2785
chr5:157477872-157478606:-	STAD	GSVA_HALLMARK_E2F_TARGETS	EER	5.8735e-08	0.2829
chr5:157477872-157478606:-	TGCT	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.4569e-07	0.4121
ENSG00000135074.14,ADAM19	TGCT	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	9.8240e-09	0.4417
ENSG00000135074.14,ADAM19	THCA	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	3.7090e-07	0.2843
chr5:157477872-157478606:-	THCA	GSVA_HALLMARK_PROTEIN_SECRETION	EER	4.0233e-03	0.1813
chr5:157477872-157478606:-	THYM	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.0208e-02	0.2380
ENSG00000135074.14,ADAM19	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.0346e-02	-0.2048
chr5:157477872-157478606:-	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	7.4248e-03	-0.2356
ENSG00000135074.14,ADAM19	UCS	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.4015e-03	0.3783
chr5:157477872-157478606:-	UCS	GSVA_HALLMARK_MYOGENESIS	EER	6.4296e-03	-0.3664

Top

7. Enriched editing regions and drugs for ADAM19

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr5:157477872-157478606:-	ACC	BMS.509744	EER	2.6519e-02	0.4047
ENSG00000135074.14,ADAM19	ACC	Camptothecin	EAG	2.3182e-02	0.3497
chr5:157477872-157478606:-	BLCA	GSK269962A	EER	2.1525e-04	0.2124
ENSG00000135074.14,ADAM19	BLCA	AMG.706	EAG	4.9072e-05	0.2246
ENSG00000135074.14,ADAM19	BRCA	DMOG	EAG	1.8912e-07	0.1626
chr5:157477872-157478606:-	BRCA	GW.441756	EER	1.0371e-06	-0.1555
chr5:157477872-157478606:-	CESC	AP.24534	EER	4.4092e-04	0.2156
ENSG00000135074.14,ADAM19	CESC	IPA.3	EAG	1.1050e-03	0.1940
ENSG00000135074.14,ADAM19	CHOL	AP.24534	EAG	1.2046e-02	0.4386
chr5:157477872-157478606:-	CHOL	CGP.60474	EER	2.4584e-03	0.5407
chr5:157477872-157478606:-	COAD	Dasatinib	EER	3.1150e-03	0.1816
ENSG00000135074.14,ADAM19	COAD	GNF.2	EAG	4.9600e-03	0.1712
ENSG00000135074.14,ADAM19	ESCA	CGP.60474	EAG	2.5977e-04	-0.2876
chr5:157477872-157478606:-	ESCA	BI.D1870	EER	1.7557e-02	-0.1905
ENSG00000135074.14,ADAM19	GBM	AICAR	EAG	1.4540e-05	-0.3515
chr5:157477872-157478606:-	GBM	GSK269962A	EER	1.5647e-04	0.3186
chr5:157477872-157478606:-	HNSC	Erlotinib	EER	4.5744e-08	-0.2523
ENSG00000135074.14,ADAM19	HNSC	Erlotinib	EAG	2.4738e-12	-0.3119
chr5:157477872-157478606:-	KIRC	Lapatinib	EER	2.6599e-06	-0.2548
ENSG00000135074.14,ADAM19	KIRC	Lapatinib	EAG	3.9463e-06	-0.2445
chr5:157477872-157478606:-	KIRP	CGP.60474	EER	1.5246e-02	0.3381
ENSG00000135074.14,ADAM19	KIRP	FH535	EAG	1.4556e-02	-0.2869
ENSG00000135074.14,ADAM19	LAML	Cytarabine	EAG	1.7036e-02	0.3429
chr5:157477872-157478606:-	LAML	Elesclomol	EER	3.0951e-02	0.3460
chr5:157477872-157478606:-	LGG	Bryostatin.1	EER	1.4082e-05	0.2532
ENSG00000135074.14,ADAM19	LGG	Embelin	EAG	6.2656e-11	0.3330
chr5:157477872-157478606:-	LIHC	BMS.509744	EER	5.2234e-03	0.1761
ENSG00000135074.14,ADAM19	LIHC	Bexarotene	EAG	5.7744e-07	0.2852
ENSG00000135074.14,ADAM19	LUAD	LFM.A13	EAG	1.6207e-04	0.1719
chr5:157477872-157478606:-	LUAD	AICAR	EER	6.4919e-04	0.1574
chr5:157477872-157478606:-	LUSC	Bexarotene	EER	4.0080e-06	0.2133
ENSG00000135074.14,ADAM19	LUSC	Bexarotene	EAG	9.2644e-07	0.2220
ENSG00000135074.14,ADAM19	MESO	GW.441756	EAG	1.0770e-02	-0.2929
chr5:157477872-157478606:-	MESO	JNJ.26854165	EER	3.8258e-03	0.3414
ENSG00000135074.14,ADAM19	OV	GSK269962A	EAG	1.6308e-07	0.3302
chr5:157477872-157478606:-	OV	GSK269962A	EER	2.9824e-04	0.2472
chr5:157477872-157478606:-	PAAD	Docetaxel	EER	1.5789e-03	0.2478
ENSG00000135074.14,ADAM19	PAAD	AZD6482	EAG	5.5650e-04	0.2675
chr5:157477872-157478606:-	PCPG	GSK269962A	EER	3.2489e-04	0.4670
ENSG00000135074.14,ADAM19	PCPG	GSK269962A	EAG	5.3347e-05	0.4518
chr5:157477872-157478606:-	PRAD	AZD6482	EER	2.2524e-03	0.2148
ENSG00000135074.14,ADAM19	PRAD	BX.795	EAG	2.2886e-04	0.2205
chr5:157477872-157478606:-	READ	Bexarotene	EER	7.9425e-03	0.2752
ENSG00000135074.14,ADAM19	READ	Bexarotene	EAG	2.6940e-02	0.2307
chr5:157477872-157478606:-	SARC	Gefitinib	EER	9.9669e-04	-0.2103
ENSG00000135074.14,ADAM19	SARC	AS601245	EAG	1.0626e-05	-0.2751
ENSG00000135074.14,ADAM19	SKCM	AMG.706	EAG	3.2838e-05	0.2063
chr5:157477872-157478606:-	SKCM	AMG.706	EER	4.9383e-06	0.2355
chr5:157477872-157478606:-	STAD	GDC0941	EER	1.4748e-04	0.2001
ENSG00000135074.14,ADAM19	STAD	GDC0941	EAG	7.3143e-04	0.1760
ENSG00000135074.14,ADAM19	TGCT	AS601245	EAG	1.5689e-09	0.4624
chr5:157477872-157478606:-	TGCT	AS601245	EER	2.0272e-07	0.4078
ENSG00000135074.14,ADAM19	THCA	GDC.0449	EAG	1.1574e-04	0.2176
chr5:157477872-157478606:-	THCA	CGP.082996	EER	9.2220e-04	0.2083
ENSG00000135074.14,ADAM19	THYM	GSK.650394	EAG	8.3411e-04	0.3155
chr5:157477872-157478606:-	THYM	AZ628	EER	3.1275e-03	0.3001
ENSG00000135074.14,ADAM19	UCEC	CMK	EAG	5.4911e-04	-0.2736
chr5:157477872-157478606:-	UCEC	Gemcitabine	EER	9.1695e-03	-0.2295
chr5:157477872-157478606:-	UCS	Cisplatin	EER	2.8585e-04	-0.4748
ENSG00000135074.14,ADAM19	UCS	AZD7762	EAG	3.3358e-03	-0.3890

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType